乙型病毒性肝炎(HBV)相关肝衰竭约占整个肝衰竭的90%,大多继发于慢性乙型肝炎、肝硬化等基础性肝病,病理表现为肝细胞大量坏死和凋亡超过了肝细胞的再生能力,进而导致局部微循环障碍,最终引起肝脏的合成代谢、分泌、解毒与免疫功能障碍[1-3]。其发病机制复杂、进展迅速、病死率高[4],治疗有其自身的特点。如何治疗才能提高HBV相关肝衰竭生存率是我们亟待解决的问题。本文结合最新的循证学证据对HBV相关慢性肝衰 Hepatitis B (HBV) -related liver failure accounts for about 90% of the total liver failure, most of which are secondary to chronic liver diseases such as chronic hepatitis B and cirrhosis. The pathological manifestation is that a large number of hepatocytes undergo necrosis and apoptosis more than hepatocytes Of the regenerative capacity, and then lead to local microcirculation, eventually causing the liver anabolic, secretory, detoxification and immune dysfunction [1-3]. Its pathogenesis is complex, rapid progress, high mortality [4], the treatment has its own characteristics. How to improve the survival rate of HBV-related liver failure is an urgent problem to be solved. This article combines the latest evidence-based evidence of HBV-related chronic liver failure